Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Journal of Acquired Immune Deficiency Syndromes (1999)|October 9, 2010
Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infectionJason V Baker, Jacqueline Neuhaus, Daniel Duprez, et al.
Nature Communications|December 2, 2024
PET-CT outcomes from a randomised controlled trial of rosuvastatin as an adjunct to standard tuberculosis treatmentGail B Cross, Intan P Sari, Sarah M Burkill, et al.
The Lancet. Infectious Diseases|November 8, 2017
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trialJames G Hakim, Jennifer Thompson, Cissy Kityo, et al.
The Lancet. HIV|April 23, 2022
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trialNicholas I Paton, Joseph Musaazi, Cissy Kityo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2005
The TREAT Asia HIV Observational Database: baseline and retrospective dataJialun Zhou, N Kumarasamy, Rossana Ditangco, et al.
The Lancet. Infectious Diseases|March 26, 2023
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trialGail B Cross, Intan P Sari, Cissy Kityo, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 23, 2023
Recent advances in the treatment of tuberculosisIlaria Motta, Martin Boeree, Dumitru Chesov, et al.
BMC Medical Genomics|June 12, 2021
A blood RNA transcriptome signature for COVID-19Philip Kam Weng Kwan, Gail B Cross, Claire M Naftalin, et al.
JAMA|July 24, 2012
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trialNicholas I Paton, Ruth L Goodall, David T Dunn, et al.
Nature Medicine|November 4, 2025
Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trialCissy Kityo, Ivan K Mambule, Joseph Musaazi, et al.
Pageof 10